Samsung C&T (028260) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
10 Mar, 2026Executive summary
Achieved 3Q25 sales of KRW 10,151 bn, up KRW 129 bn YoY, with operating profit at KRW 994 bn, up KRW 241 bn YoY.
Net profit rose to KRW 885 bn, a KRW 358 bn increase YoY, driven by strong Bio and F&B segments.
Gross profit improved by KRW 250 bn YoY, with OP margin rising to 9.8% from 7.5% YoY.
Financial highlights
YTD sales reached KRW 29,910 bn, down KRW 2,201 bn YoY, but operating profit YTD increased by KRW 123 bn.
Gross profit for 3Q25 was KRW 2,051 bn, up KRW 250 bn YoY.
Non-operating profit improved by KRW 174 bn YoY, with financial profit up KRW 38 bn.
Net cash position increased to KRW 2,475 bn, up KRW 685 bn from the previous quarter.
Outlook and guidance
E&C annual new order guidance set at KRW 5.0 tn, with 3Q25 new orders already at KRW 7.4 tn.
Focus on expanding global business in F&B and Bio, and leveraging new partnerships in SMR and solar PV.
Latest events from Samsung C&T
- 2Q24 delivered robust profit growth, led by Bio and F&B, amid ongoing business diversification.028260
Q2 202410 Mar 2026 - 3Q24 profit declined year-over-year, but F&B and bio segments showed strong growth.028260
Q3 202410 Mar 2026 - Net profit rose 15% year-over-year in 4Q 2024, driven by Bio and T&I growth.028260
Q4 202410 Mar 2026 - Net profit rose 14% year-over-year as Bio and T&I growth offset declines in other segments.028260
Q1 202510 Mar 2026 - Sequential sales and operating profit rose, but net profit fell; Bio outlook upgraded.028260
Q2 202510 Mar 2026 - Net profit surged YoY in 4Q25, with Bio and E&C driving growth and a positive 2026 outlook.028260
Q4 202510 Mar 2026